HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TRAW
Traws Pharma, Inc.
There isn't enough reported data to score TRAW yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TRAW Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TRAW's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TRAW PE Valuation
TRAW has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TRAW Forward outlook
There aren't enough analyst estimates for TRAW to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TRAW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.85 | +$26.27 |
| Q1 2026 | -$1.80 | +$147.96 |
| Q4 2025 | $0.82 | +$158.67 |
| Q3 2025 | -$19.65 | +$121.66 |
| Q2 2025 | -$28.12 | +$110.13 |
| Q1 2025 | -$149.76 | -$128.26 |
| Q4 2024 | -$157.85 | -$135.35 |
| Q3 2024 | -$141.31 | -$117.06 |
TRAW has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus down 100% for TRAW.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TRAW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $2.7M | +4695% |
| Q1 2025 | $57K | +1.8% |
| Q4 2024 | $56K | 0% |
| Q3 2024 | $57K | 0% |
| Q2 2024 | $57K | 0% |
| Q1 2024 | $56K | 0% |
| Q4 2023 | $56K | 0% |
| Q3 2023 | $57K | 0% |
TRAW's revenue has picked up after four years of holding roughly level: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -46% | +216354 points |
| Q1 2025 | -9128% | +179 points |
| Q4 2024 | -9425% | -1457 points |
| Q3 2024 | -14975% | -6047 points |
| Q2 2024 | -216400% | -208312 points |
| Q1 2024 | -9307% | +1652 points |
| Q4 2023 | -7968% | +2271 points |
| Q3 2023 | -8928% | +968 points |
TRAW's operating margin was −46% last quarter, up 216354 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
TRAW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.6M | +$2.9M |
| Q4 2025 | -$2.8M | +$1.3M |
| Q1 2025 | -$5.4M | -$1M |
| Q4 2024 | -$4M | +$390K |
| Q1 2024 | -$4.4M | +$119K |
| Q4 2023 | -$4.4M | -$546K |
| Q2 2023 | -$4.5M | -$276K |
| Q1 2023 | -$4.5M | -$247K |
TRAW has burned cash in almost every quarter: −$18M over the past year, against −$24M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TRAW on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TRAW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +49% | +5.2M shares |
| 1 year | +120% | +8.6M shares |
| 3 years | +1797% | +15M shares |
| 5 years | +3318% | +15.4M shares |
| Available history | +96762% | +15.8M shares |
TRAW has 16M diluted shares, up 120% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TRAW Net Leverage
TRAW's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TRAW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.6 | Neutral |
| Stochastic | 5.5 | Oversold |
TRAW's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TRAW PE vs Healthcare Sector
TRAW has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TRAW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.39 | 28% below |
| 20 week MA | $0.50 | 44% below |
| 50 week MA | $1.19 | 76% below |
| 100 week MA | $2.12 | 87% below |
| 200 week MA | $9.74 | 97% below |
TRAW is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over TRAW on returns for 2026, with the stronger performance.
TRAW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $153.8 | $176.3 | +15% |
| 2021 | $176.3 | $71.3 | -60% |
| 2022 | $71.3 | $16.5 | -77% |
| 2023 | $16.5 | $18.8 | +14% |
| 2024 | $18.8 | $13.4 | -28% |
| 2025 | $13.4 | $1.17 | -91% |
| 2026 YTD | $1.17 | $0.28 | -76% |
TRAW has finished lower in four of the last six years. It's down 76% so far in 2026.